Joinn Laboratories(China)Co.,Ltd. (603127.SS)
CNY 17.42
(0.87%)
CNY 17.42
(0.87%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -2.77 Billion CNY | 1.84% |
| 2022 | -2.82 Billion CNY | 30.3% |
| 2021 | -4.05 Billion CNY | -1327.97% |
| 2020 | -284.23 Million CNY | -83.81% |
| 2019 | -154.63 Million CNY | -11.09% |
| 2018 | -139.19 Million CNY | 65.6% |
| 2017 | -404.61 Million CNY | -204.91% |
| 2016 | -132.69 Million CNY | -109.77% |
| 2015 | -63.26 Million CNY | -3263.67% |
| 2014 | -1.88 Million CNY | -105.1% |
| 2013 | 36.85 Million CNY | -52.12% |
| 2012 | 76.97 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | -1.8 Billion CNY | 14.27% |
| 2024 Q1 | -2.8 Billion CNY | -0.89% |
| 2024 Q2 | -2.1 Billion CNY | 25.0% |
| 2023 Q4 | -2.77 Billion CNY | 1.39% |
| 2023 Q1 | -2.87 Billion CNY | -1.64% |
| 2023 FY | -2.77 Billion CNY | 1.84% |
| 2023 Q3 | -2.81 Billion CNY | 4.86% |
| 2023 Q2 | -2.96 Billion CNY | -2.94% |
| 2022 Q4 | -2.82 Billion CNY | -1.98% |
| 2022 FY | -2.82 Billion CNY | 30.3% |
| 2022 Q3 | -2.77 Billion CNY | 25.26% |
| 2022 Q2 | -3.71 Billion CNY | 12.36% |
| 2022 Q1 | -4.23 Billion CNY | -4.35% |
| 2021 Q3 | -4.04 Billion CNY | 2.0% |
| 2021 Q1 | -5.58 Billion CNY | -1863.33% |
| 2021 FY | -4.05 Billion CNY | -1327.97% |
| 2021 Q2 | -4.13 Billion CNY | 25.99% |
| 2021 Q4 | -4.05 Billion CNY | -0.28% |
| 2020 FY | -284.23 Million CNY | -83.81% |
| 2020 Q3 | -173.66 Million CNY | -0.92% |
| 2020 Q4 | -284.23 Million CNY | -63.67% |
| 2020 Q2 | -172.07 Million CNY | -8.09% |
| 2020 Q1 | -159.19 Million CNY | -2.95% |
| 2019 Q1 | -253.9 Million CNY | -70.76% |
| 2019 FY | -154.63 Million CNY | -11.09% |
| 2019 Q4 | -154.63 Million CNY | 5.9% |
| 2019 Q3 | -164.33 Million CNY | 15.95% |
| 2019 Q2 | -195.52 Million CNY | 23.0% |
| 2018 Q4 | -148.69 Million CNY | 45.44% |
| 2018 Q2 | -197.43 Million CNY | 49.39% |
| 2018 Q1 | -390.15 Million CNY | 3.57% |
| 2018 FY | -139.19 Million CNY | 65.6% |
| 2018 Q3 | -272.54 Million CNY | -38.04% |
| 2017 Q2 | -158.91 Million CNY | -219.75% |
| 2017 Q3 | -409.71 Million CNY | -157.82% |
| 2017 FY | -404.61 Million CNY | -204.91% |
| 2017 Q1 | 132.69 Million CNY | 200.0% |
| 2017 Q4 | -404.61 Million CNY | 1.24% |
| 2016 FY | -132.69 Million CNY | -109.77% |
| 2016 Q4 | -132.69 Million CNY | 0.0% |
| 2015 FY | -63.26 Million CNY | -3263.67% |
| 2014 FY | -1.88 Million CNY | -105.1% |
| 2013 FY | 36.85 Million CNY | -52.12% |
| 2012 FY | 76.97 Million CNY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Shanghai Runda Medical Technology Co., Ltd. | 5.96 Billion CNY | 146.549% |
| WuXi AppTec Co., Ltd. | -4.24 Billion CNY | 34.606% |
| Autobio Diagnostics Co., Ltd. | -448.29 Million CNY | -519.489% |
| Thalys Medical Technology Group Inc. | 772.55 Million CNY | 459.473% |
| Guangzhou Kingmed Diagnostics Group Co., Ltd. | -1.87 Billion CNY | -47.823% |
| Chemclin Diagnostics Co., Ltd. | -214.05 Million CNY | -1197.388% |